Scinai Immunotherapeutics Holds Annual Shareholder Meeting

TL;DR

Scinai Immunotherapeutics (SCNI) held its annual shareholder meeting on Nov 21, 2024, with over 3.4B shares eligible to vote.

AI Summary

On November 21, 2024, Scinai Immunotherapeutics Ltd. held its Annual Meeting of Shareholders. The total number of ordinary shares eligible to vote was 3,411,983,584. The company previously operated under the name BiondVax Pharmaceuticals Ltd. before changing it on June 24, 2014.

Why It Matters

This filing confirms the company's operational status and provides key details about its shareholder structure as of the meeting date.

Risk Assessment

Risk Level: low — This is a routine administrative filing confirming a shareholder meeting and share count, with no new financial or operational developments.

Key Numbers

• 3,411,983,584 — Ordinary Shares (Total number of shares entitled to vote at the Annual Meeting of Shareholders on November 21, 2024.)

Key Players & Entities

• Scinai Immunotherapeutics Ltd. (company) — Registrant
• BiondVax Pharmaceuticals Ltd. (company) — Former company name
• 3,411,983,584 (dollar_amount) — Ordinary shares entitled to vote
• November 21, 2024 (date) — Annual Meeting of Shareholders date
• June 24, 2014 (date) — Date of name change from BiondVax Pharmaceuticals Ltd.

FAQ

From the Filing

0001213900-24-101231.txt : 20241122 0001213900-24-101231.hdr.sgml : 20241122 20241122083856 ACCESSION NUMBER: 0001213900-24-101231 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20241122 FILED AS OF DATE: 20241122 DATE AS OF CHANGE: 20241122 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Scinai Immunotherapeutics Ltd. CENTRAL INDEX KEY: 0001611747 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37353 FILM NUMBER: 241486652 BUSINESS ADDRESS: STREET 1: JERUSALEM BIOPARK, 2ND FLOOR STREET 2: HADASSAH EIN KEREM CAMPUS CITY: JERUSALEM STATE: L3 ZIP: 00000 BUSINESS PHONE: 972-8-9302529 MAIL ADDRESS: STREET 1: JERUSALEM BIOPARK, 2ND FLOOR STREET 2: HADASSAH EIN KEREM CAMPUS CITY: JERUSALEM STATE: L3 ZIP: 00000 FORMER COMPANY: FORMER CONFORMED NAME: BiondVax Pharmaceuticals Ltd. DATE OF NAME CHANGE: 20140624 6-K 1 ea0222250-6k_scinai.htm REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of November 2024 Commission File Number: 001-37353 SCINAI IMMUNOTHERAPEUTICS LTD. (Translation of registrant’s name into English) Jerusalem BioPark, 2nd Floor Hadassah Ein Kerem Campus Jerusalem, Israel (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐ On November 21, 2024, Scinai Immunotherapeutics Ltd (the “Company”) held an Annual Meeting of Shareholders (the “Meeting”). The total number of ordinary shares of the Company entitled to vote at the Meeting was 3,411,983,584 Ordinary Shares (each 4,000 Ordinary Shares represented by one American Depository Share (“ADS”)) and there were present, in person or by proxy, 3,411,774,240 ordinary shares, which constituted a quorum for the Meeting. The matters voted upon, and the results of the vote were as follows: Proposal 1: To approve the re-election of Mr. Amir Reichman to the board of directors, to serve until the third annual meeting after the meeting. The shareholders approved the re-election of Mr. Amir Reichman to the board of directors, to serve until the third annual meeting after the meeting: FOR AGAINST ABSTAIN 567,008,000 (141,752 ADSs) 24,492,000 (6,123 ADSs) 568,000 (142 ADSs) Proposal 2: To approve the re-election of Dr. Morris Laster to the board of directors, to serve until the third annual meeting after the meeting. The shareholders approved the re-election of Dr. Morris Laster to the board of directors, to serve until the third annual meeting after the meeting: FOR AGAINST ABSTAIN 566,712,000 (141,678 ADSs) 22,376,000 (5,594 ADSs) 1,620,000 (405 ADSs) Proposal 3: To approve the re-election of Mr. Jay Green to the board of directors, to serve until the third annual meeting after the meeting. The shareholders approved the re-election of Mr. Jay Green to the board of directors, to serve until the third annual meeting after the meeting: FOR AGAINST ABSTAIN 568,092,000 (142,023 ADSs) 23,412,000 (5,853ADSs) 564,000 (141 ADSs) Proposal 4: To approve the re-election of Dr. Yael Margolin to the board of directors, to serve until the first annual meeting after the meeting. The shareholders approved the re-election of Dr. Yael Margolin to the board of directors, to serve until the first annual meeting after the meeting: FOR AGAINST ABSTAIN 567,800,000 (141,950 ADSs) 22,640,000 (5,660 ADSs) 1,628,000 (407 ADSs) 1 Proposal 5: To approve the re-election of Mr. Adi Raviv to the board of directors, to serve until the first annual meeting after the meeting. The shareholders approved the re-elect